Relay Therapeutics, Inc. RLAY
17.44 USD +0.16 (+0.93%)
At closeNov 3, 2026, 4:00 PM EST
17.44 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
17.28 Day range 18.00
5.95 52-week range 21.27
- YTD
- +106.15%
- 1 year
- +151.30%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 27.58 +58.2% upside
Now 17.44
- Target (low)
- 20.00
- Target (mean)
- 27.58
- Target (high)
- 32.00
Ratings (0m) 13 13 buy · 0 hold · 0 sell
- Strong buy3
- Buy10
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 13
- 1 month ago 13
- 2 months ago 14
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.40119 | -0.43 – -0.36 | -0.43 | +6.7% | 1.58M | 0.0% | 11 |
| Next quarter | -0.37949 | -0.46 – -0.29 | -0.31 | -22.4% | 7.77M | +11.0% | 11 |
| Current year | -1.61 | -1.72 – -1.47 | -1.61 | -0.2% | 11.19M | -27.2% | 11 |
| Next year | -1.63 | -1.83 – -1.11 | -1.61 | -1.1% | 17.91M | +60.2% | 11 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 20, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 14, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 10, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Aug 7, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jul 21, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Jul 16, 2026 | Canaccord Genuity | Initiated | — | Buy |
| Jul 8, 2026 | JP Morgan | Initiated | — | Overweight |
| May 26, 2026 | Guggenheim | Maintained | Buy | Buy |
| May 26, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 20, 2026 | Barclays | Maintained | Overweight | Overweight |
| May 20, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| May 19, 2026 | Raymond James | Maintained | Strong Buy | Strong Buy |
| Apr 29, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 28, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Apr 28, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Apr 28, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Apr 28, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Apr 14, 2026 | Jones Trading | Initiated | — | Hold |
| Apr 8, 2026 | Barclays | Maintained | Overweight | Overweight |
| Mar 23, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 17, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Mar 17, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Mar 13, 2026 | Guggenheim | Maintained | Buy | Buy |
| Feb 27, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Jan 26, 2026 | Oppenheimer | Upgrade | Perform | Outperform |
| Dec 12, 2025 | Wells Fargo | Upgrade | Equal-Weight | Overweight |
| Nov 7, 2025 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Aug 26, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 8, 2025 | Raymond James | Maintained | Strong Buy | Strong Buy |
| May 7, 2025 | Guggenheim | Maintained | Buy | Buy |